HIV-1 Vif versus the APOBEC3 cytidine deaminases: An intracellular duel between pathogen and host restriction factors

Molecular Aspects of Medicine

Volumn 31, Issue 5, 2010, Pages 383-397

  Wissing, Silke ^a   Galloway, Nicole L K ^a   Greene, Warner C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV 1

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CULLIN; CYTIDINE DEAMINASE; IMB 26; IMB 35; PROTEASOME; RN 18; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN;

DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; UBIQUITINATION; VIRION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION;

CYTOSINE DEAMINASE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INTRACELLULAR SPACE; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77958486207     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2010.06.001     Document Type: Review

References (197)

1. An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B., Alobwede I., Trono D., Vlahov D., Donfield S., et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 2004, 78:11070-11076.
2. An P., Duggal P., Wang L.H., O'Brien S.J., Donfield S., Goedert J.J., Phair J., Buchbinder S., Kirk G.D., Winkler C.A. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 2007, 3:e19.
3. Anderson J.L., Hope T.J. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 2008, 375:1-12.
4. Auclair J.R., Green K.M., Shandilya S., Evans J.E., Somasundaran M., Schiffer C.A. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 2007, 69:270-284.
5. Bardy M., Gay B., Pebernard S., Chazal N., Courcoul M., Vigne R., Decroly E., Boulanger P. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J. Gen. Virol. 2001, 82:2719-2733.
6. Berkhout B., de Ronde A. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 2004, 18:1861-1863.
7. Bernacchi S., Henriet S., Dumas P., Paillart J.C., Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J. Biol. Chem. 2007, 282:26361-26368.
8. Betts L., Xiang S., Short S.A., Wolfenden R., Carter C.W. Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol. 1994, 235:635-656.
9. Biasin M., Piacentini L., Lo Caputo S., Kanari Y., Magri G., Trabattoni D., Naddeo V., Lopalco L., Clivio A., Cesana E., et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J. Infect. Dis. 2007, 195:960-964.
10. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 2004, 5:1109-1115.
11. Bishop K.N., Holmes R.K., Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 2006, 80:8450-8458.
12. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 2004, 14:1392-1396.
13. Bishop K.N., Holmes R.K., Sheehy A.M., Malim M.H. APOBEC-mediated editing of viral RNA. Science 2004, 305:645.
14. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4:e1000231.
15. Bogerd H.P., Cullen B.R. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 2008, 14:1228-1236.
16. Bogerd H.P., Doehle B.P., Wiegand H.L., Cullen B.R. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. USA 2004, 101:3770-3774.
17. Bogerd H.P., Wiegand H.L., Doehle B.P., Cullen B.R. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 2007, 364:486-493.
18. Bourara K., Liegler T.J., Grant R.M. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog. 2007, 3:1477-1485.
19. Burnett A., Spearman P. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 2007, 81:5000-5013.
20. Camaur D., Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 1996, 70:6106-6111.
21. Cao J., Isaacson J., Patick A.K., Blair W.S. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob. Agents Chemother. 2005, 49:3833-3841.
22. Cen, S., Peng, Z., Li, X., Li, Z., Ma, J., Wang, Y., Bo Fan, X.-F.Y., Wang, Yu-Ping, Liu, Fei, Shao, Rong-Guang, Zhao, Li-Xun, Yu, Liyan, Jiang, Jian-Dong, 2010. Small molecular inhibitors for HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. April 2.
23. Chelico L., Pham P., Calabrese P., Goodman M.F. APOBEC3G DNA deaminase acts processively 3′→5′ on single-stranded DNA. Nat. Struct. Mol. Biol. 2006, 13:392-399.
24. Chen G., He Z., Wang T., Xu R., Yu X.F. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 2009, 83:8674-8682.
25. Chen K.M., Harjes E., Gross P.J., Fahmy A., Lu Y., Shindo K., Harris R.S., Matsuo H. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 2008, 452:116-119.
26. Chiu Y.L., Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 2008, 26:317-353.
27. Chiu Y.L., Soros V.B., Kreisberg J.F., Stopak K., Yonemoto W., Greene W.C. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005, 435:108-114.
28. Cho S.J., Drechsler H., Burke R.C., Arens M.Q., Powderly W., Davidson N.O. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J. Virol. 2006, 80:2069-2072.
29. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 2003, 13:2009-2013.
30. Conticello S.G., Thomas C.J., Petersen-Mahrt S.K., Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 2005, 22:367-377.
31. Courcoul M., Patience C., Rey F., Blanc D., Harmache A., Sire J., Vigne R., Spire B. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J. Virol. 1995, 69:2068-2074.
32. Dang Y., Davis R.W., York I.A., Zheng Y.H. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 virus Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 2010, 84:5741-5750.
33. Dang Y., Siew L.M., Wang X., Han Y., Lampen R., Zheng Y.H. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 2008, 283:11606-11614.
34. Dang Y., Siew L.M., Zheng Y.H. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J. Biol. Chem. 2008, 283:13124-13131.
35. Dang Y., Wang X., Esselman W.J., Zheng Y.H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 2006, 80:10522-10533.
36. Dang Y., Wang X., Zhou T., York I.A., Zheng Y.H. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 2009, 83:8544-8552.
37. DeHart J.L., Bosque A., Harris R.S., Planelles V. Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J. Virol. 2008, 82:9265-9272.
38. Dettenhofer M., Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 1999, 73:1460-1467.
39. Do H., Vasilescu A., Diop G., Hirtzig T., Heath S.C., Coulonges C., Rappaport J., Therwath A., Lathrop M., Matsuda F., et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J. Infect. Dis. 2005, 191:159-163.
40. Doehle B.P., Schafer A., Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005, 339:281-288.
41. Donahue J.P., Vetter M.L., Mukhtar N.A., D'Aquila R.T. The HIV-1 motif is necessary for human APOBEC3G binding and degradation. Virology 2008, 377:49-53.
42. Fan L., Peden K. Cell-free transmission of Vif mutants of HIV-1. Virology 1992, 190:19-29.
43. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987, 237:888-893.
44. Fouchier R.A., Simon J.H., Jaffe A.B., Malim M.H. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 1996, 70:8263-8269.
45. Friew Y.N., Boyko V., Hu W.S., Pathak V.K. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 2009, 6:56.
46. Fujita M., Akari H., Sakurai A., Yoshida A., Chiba T., Tanaka K., Strebel K., Adachi A. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect. 2004, 6:791-798.
47. Fujita M., Sakurai A., Yoshida A., Miyaura M., Koyama A.H., Sakai K., Adachi A. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif. J. Virol. 2003, 77:1626-1632.
48. Furukawa A., Nagata T., Matsugami A., Habu Y., Sugiyama R., Hayashi F., Kobayashi N., Yokoyama S., Takaku H., Katahira M. Structure and real-time monitoring of the enzymatic reaction of APOBEC3G which is involved in anti-HIV activity. Nucleic Acids Symp. Ser. 2009, 87:88.
49. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 1992, 66:6489-6495.
50. Gaddis N.C., Chertova E., Sheehy A.M., Henderson L.E., Malim M.H. Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J. Virol. 2003, 77:5810-5820.
51. Gallo R., Wong-Staal F., Montagnier L., Haseltine W.A., Yoshida M. HIV/HTLV gene nomenclature. Nature 1988, 333:504.
52. Gandhi S.K., Siliciano J.D., Bailey J.R., Siliciano R.F., Blankson J.N. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 2008, 82:3125-3130.
53. Giri K., Maynard E.L. Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. Biopolymers 2009, 92:417-425.
54. Goila-Gaur R., Khan M.A., Miyagi E., Strebel K. Differential sensitivity of " old" versus " new" APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol. 2009, 83:1156-1160.
55. Goncalves J., Korin Y., Zack J., Gabuzda D. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 1996, 70:8701-8709.
56. Gooch B.D., Cullen B.R. Functional domain organization of human APOBEC3G. Virology 2008, 379:118-124.
57. Guo F., Cen S., Niu M., Saadatmand J., Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 2006, 80:11710-11722.
58. Guo F., Cen S., Niu M., Yang Y., Gorelick R.J., Kleiman L. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 2007, 81:11322-11331.
59. Guo F., Saadatmand J., Niu M., Kleiman L. Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) annealing to viral RNA in human immunodeficiency virus type 1. J. Virol. 2009, 83:8099-8107.
60. Hache G., Liddament M.T., Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005, 280:10920-10924.
61. Harari A., Ooms M., Mulder L.C., Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 2009, 83:295-303.
62. Harjes E., Gross P.J., Chen K.M., Lu Y., Shindo K., Nowarski R., Gross J.D., Kotler M., Harris R.S., Matsuo H. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 2009, 389:819-832.
63. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809.
64. He Z., Zhang W., Chen G., Xu R., Yu X.F. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 2008, 381:1000-1011.
65. Henriet S., Mercenne G., Bernacchi S., Paillart J.C., Marquet R. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev. 2009, 73:211-232.
66. Henriet S., Richer D., Bernacchi S., Decroly E., Vigne R., Ehresmann B., Ehresmann C., Paillart J.C., Marquet R. Cooperative and specific binding of Vif to the 5′ region of HIV-1 genomic RNA. J. Mol. Biol. 2005, 354:55-72.
67. Hoglund S., Ohagen A., Lawrence K., Gabuzda D. Role of vif during packing of the core of HIV-1. Virology 1994, 201:349-355.
68. Holden L.G., Prochnow C., Chang Y.P., Bransteitter R., Chelico L., Sen U., Stevens R.C., Goodman M.F., Chen X.S. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 2008, 456:121-124.
69. Holmes R.K., Koning F.A., Bishop K.N., Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282:2587-2595.
70. Huthoff H., Autore F., Gallois-Montbrun S., Fraternali F., Malim M.H. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 2009, 5:e1000330.
71. Huthoff H., Malim M.H. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 2007, 81:3807-3815.
72. Iwatani Y., Chan D.S., Liu L., Yoshii H., Shibata J., Yamamoto N., Levin J.G., Gronenborn A.M., Sugiura W. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. USA 2009, 106:19539-19544.
73. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007, 35:7096-7108.
74. Iwatani Y., Takeuchi H., Strebel K., Levin J.G. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 2006, 80:5992-6002.
75. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
76. Jin X., Brooks A., Chen H., Bennett R., Reichman R., Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 2005, 79:11513-11516.
77. Kaiser S.M., Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 2006, 80:875-882.
78. Kamata M., Nagaoka Y., Chen I.S. Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog. 2009, 5:e1000342.
79. Kao S., Goila-Gaur R., Miyagi E., Khan M.A., Opi S., Takeuchi H., Strebel K. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 2007, 369:329-339.
80. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 2003, 77:11398-11407.
81. Kao S., Miyagi E., Khan M.A., Takeuchi H., Opi S., Goila-Gaur R., Strebel K. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 2004, 1:27.
82. Kataropoulou A., Bovolenta C., Belfiore A., Trabatti S., Garbelli A., Porcellini S., Lupo R., Maga G. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res. 2009, 37:3660-3669.
83. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105:7552-7557.
84. Khan M.A., Aberham C., Kao S., Akari H., Gorelick R., Bour S., Strebel K. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 2001, 75:7252-7265.
85. Khan M.A., Goila-Gaur R., Kao S., Miyagi E., Walker R.C., Strebel K. Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 2009, 6:99.
86. Khan M.A., Goila-Gaur R., Opi S., Miyagi E., Takeuchi H., Kao S., Strebel K. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 2007, 4:48.
87. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 2005, 79:5870-5874.
88. Kieffer T.L., Kwon P., Nettles R.E., Han Y., Ray S.C., Siliciano R.F. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 2005, 79:1975-1980.
89. Kijak G.H., Janini L.M., Tovanabutra S., Sanders-Buell E., Arroyo M.A., Robb M.L., Michael N.L., Birx D.L., McCutchan F.E. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 2008, 376:101-111.
90. Kobayashi M., Takaori-Kondo A., Miyauchi Y., Iwai K., Uchiyama T. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-ElonginB-ElonginC complex is essential for Vif function. J. Biol. Chem. 2005, 280:18573-18578.
91. Koning F.A., Newman E.N., Kim E.Y., Kunstman K.J., Wolinsky S.M., Malim M.H. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 2009, 83:9474-9485.
92. Koulinska I.N., Chaplin B., Mwakagile D., Essex M., Renjifo B. Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res. Human Retroviruses 2003, 19:1115-1123.
93. Kreisberg J.F., Yonemoto W., Greene W.C. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 2006, 203:865-870.
94. Lafferty M.K., Sun L., DeMasi L., Lu W., Garzino-Demo A. CCR6 ligands inhibit HIV by inducing APOBEC3G. Blood 2010, 115:1564-1571.
95. Land A.M., Ball T.B., Luo M., Pilon R., Sandstrom P., Embree J.E., Wachihi C., Kimani J., Plummer F.A. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 2008, 82:8172-8182.
96. Langlois M.A., Neuberger M.S. Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J. Virol. 2008, 82:4660-4664.
97. Li J., Potash M.J., Volsky D.J. Functional domains of APOBEC3G required for antiviral activity. J. Cell Biochem. 2004, 92:560-572.
98. Li M.M., Wu L.I., Emerman M. The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 2009, 84:88-95.
99. Li X.Y., Guo F., Zhang L., Kleiman L., Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 2007, 282:32065-32074.
100. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 2004, 14:1385-1391.
101. Liu H., Wu X., Newman M., Shaw G.M., Hahn B.H., Kappes J.C. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J. Virol. 1995, 69:7630-7638.
102. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 2004, 78:11841-11852.
103. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 2007, 81:7238-7248.
104. Luo K., Xiao Z., Ehrlich E., Yu Y., Liu B., Zheng S., Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. USA 2005, 102:11444-11449.
105. Madani N., Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 1998, 72:10251-10255.
106. Malim M.H., Emerman M. HIV-1 accessory proteins - ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398.
107. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
108. Mangeat B., Turelli P., Liao S., Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 2004, 279:14481-14483.
109. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
110. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9:1398-1403.
111. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 2007, 81:7099-7110.
112. Mehle A., Goncalves J., Santa-Marta M., McPike M., Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004, 18:2861-2866.
113. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 2004, 279:7792-7798.
114. Mehle A., Thomas E.R., Rajendran K.S., Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 2006, 281:17259-17265.
115. Mercenne G., Bernacchi S., Richer D., Bec G., Henriet S., Paillart J.C., Marquet R. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res. 2010, 38:633-646.
116. Miller J.H., Presnyak V., Smith H.C. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 2007, 4:81.
117. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 2007, 81:13346-13353.
118. Mulder L.C., Harari A., Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. USA 2008, 105:5501-5506.
119. Nathans R., Cao H., Sharova N., Ali A., Sharkey M., Stranska R., Stevenson M., Rana T.M. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 2008, 26:1187-1192.
120. Navarro F., Bollman B., Chen H., Konig R., Yu Q., Chiles K., Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333:374-386.
121. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15:166-170.
122. Nowarski R., Britan-Rosich E., Shiloach T., Kotler M. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 2008, 15:1059-1066.
123. Nowotny B., Schneider T., Pradel G., Schirmeister T., Rethwilm A., Kirschner M. Inducible APOBEC3G-Vif double stable cell line as a high throughput screening platform to identify antiviral compounds. Antimicrob. Agents Chemother. 2010, 54:78-87.
124. Oberste M.S., Gonda M.A. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 1992, 6:95-102.
125. OhAinle M., Kerns J.A., Li M.M., Malik H.S., Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 2008, 4:249-259.
126. OhAinle M., Kerns J.A., Malik H.S., Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 2006, 80:3853-3862.
127. Opi S., Kao S., Goila-Gaur R., Khan M.A., Miyagi E., Takeuchi H., Strebel K. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 2007, 81:8236-8246.
128. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 2006, 80:9259-9269.
129. Paul I., Cui J., Maynard E.L. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. USA 2006, 103:18475-18480.
130. Peng G., Greenwell-Wild T., Nares S., Jin W., Lei K.J., Rangel Z.G., Munson P.J., Wahl S.M. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 2007, 110:393-400.
131. Pery E., Rajendran K.S., Brazier A.J., Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 2009, 83:2374-2381.
132. Piantadosi A., Humes D., Chohan B., McClelland R.S., Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J. Virol. 2009, 83:7805-7814.
133. Pion M., Granelli-Piperno A., Mangeat B., Stalder R., Correa R., Steinman R.M., Piguet V. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J. Exp. Med. 2006, 203:2887-2893.
134. Prochnow C., Bransteitter R., Klein M.G., Goodman M.F., Chen X.S. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 2007, 445:447-451.
135. Reddy, K.W., Cheryl, A., Werner, Lise, Mlisana, Koleka, Abdool, Karim, Salim, S., Ndung'u, Thumbi, the CAPRISA Acute Infection Study Team, 2010. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 24, 195-204.
136. Reingewertz T.H., Benyamini H., Lebendiker M., Shalev D.E., Friedler A. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Eng. Des. Sel. 2009, 22:281-287.
137. Russell R.A., Moore M.D., Hu W.S., Pathak V.K. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 2009, 6:16.
138. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007, 81:8201-8210.
139. Russell R.A., Smith J., Barr R., Bhattacharyya D., Pathak V.K. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 2009, 83:1992-2003.
140. Sakai K., Dimas J., Lenardo M.J. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc. Natl. Acad. Sci. USA 2006, 103:3369-3374.
141. Santa-Marta M., da Silva F.A., Fonseca A.M., Goncalves J. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 2005, 280:8765-8775.
142. Santoni de Sio F.R., Trono D. APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS One 2009, 4:e6571.
143. Sawyer S.L., Emerman M., Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2:E275.
144. Schafer A., Bogerd H.P., Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004, 328:163-168.
145. Schrofelbauer B., Chen D., Landau N.R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. USA 2004, 101:3927-3932.
146. Schrofelbauer B., Senger T., Manning G., Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 2006, 80:5984-5991.
147. Schrofelbauer B., Yu Q., Zeitlin S.G., Landau N.R. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 2005, 79:10978-10987.
148. Schumacher A.J., Hache G., Macduff D.A., Brown W.L., Harris R.S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 2008, 82:2652-2660.
149. Shao Q., Wang Yudi, Hildreth James E.K., Liu Bindong Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif. J. Virol. 2010, 84:4840-4844.
150. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
151. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9:1404-1407.
152. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 2003, 278:44412-44416.
153. Simm M., Shahabuddin M., Chao W., Allan J.S., Volsky D.J. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J. Virol. 1995, 69:4582-4586.
154. Simon J.H., Carpenter E.A., Fouchier R.A., Malim M.H. Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J. Virol. 1999, 73:2667-2674.
155. Simon J.H., Gaddis N.C., Fouchier R.A., Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 1998, 4:1397-1400.
156. Simon J.H., Malim M.H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 1996, 70:5297-5305.
157. Simon J.H., Miller D.L., Fouchier R.A., Malim M.H. Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology 1998, 248:182-187.
158. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 2005, 1:e6.
159. Sodroski J., Goh W.C., Rosen C., Tartar A., Portetelle D., Burny A., Haseltine W. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 1986, 1549:1553.
160. Soros V.B., Yonemoto W., Greene W.C. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007, 3:e15.
161. Sova P., Volsky D.J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 1993, 67:6322-6326.
162. Stanley B.J., Ehrlich E.S., Short L., Yu Y., Xiao Z., Yu X.F., Xiong Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 2008, 82:8656-8663.
163. Stevenson M., Stanwick T.L., Dempsey M.P., Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990, 9:1551-1560.
164. Stopak K.S., Chiu Y.L., Kropp J., Grant R.M., Greene W.C. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 2007, 282:3539-3546.
165. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12:591-601.
166. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987, 328:728-730.
167. Suspene R., Rusniok C., Vartanian J.P., Wain-Hobson S. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 2006, 34:4677-4684.
168. Suspene R., Sommer P., Henry M., Ferris S., Guetard D., Pochet S., Chester A., Navaratnam N., Wain-Hobson S., Vartanian J.P. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 2004, 32:2421-2429.
169. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., Pathak V.K. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 2004, 279:35822-35828.
170. Tian C., Yu X., Zhang W., Wang T., Xu R., Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 2006, 80:3112-3115.
171. Vartanian J.P., Meyerhans A., Asjo B., Wain-Hobson S. Selection, recombination, and G-A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 1991, 65:1779-1788.
172. von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 1993, 67:4945-4955.
173. Walker R.C., Khan M.A., Kao S., Goila-Gaur R., Miyagi E., Strebel K. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J. Virol. 2010, 84:5201-5211.
174. Wang J., Shackelford J.M., Selliah N., Shivers D.K., O'Neill E., Garcia J.V., Muthumani K., Weiner D., Yu X.F., Gabuzda D., et al. The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol. 2008, 27:267-277.
175. Wang T., Tian C., Zhang W., Luo K., Sarkis P.T., Yu L., Liu B., Yu Y., Yu X.F. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 2007, 81:13112-13124.
176. Wichroski M.J., Ichiyama K., Rana T.M. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 2005, 280:8387-8396.
177. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004, 23:2451-2458.
178. Xiao Z., Ehrlich E., Luo K., Xiong Y., Yu X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 2007, 21:217-222.
179. Xiao Z., Ehrlich E., Yu Y., Luo K., Wang T., Tian C., Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006, 349:290-299.
180. Xu H., Chertova E., Chen J., Ott D.E., Roser J.D., Hu W.S., Pathak V.K. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007, 360:247-256.
181. Xu H., Svarovskaia E.S., Barr R., Zhang Y., Khan M.A., Strebel K., Pathak V.K. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. USA 2004, 101:5652-5657.
182. Yamashita T., Kamada K., Hatcho K., Adachi A., Nomaguchi M. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 2008, 10:1142-1149.
183. Yamashita T., Nomaguchi M., Miyake A., Uchiyama T., Adachi A. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity. Microbes Infect. 2010, 12:166-171.
184. Yang B., Chen K., Zhang C., Huang S., Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 2007, 282:11667-11675.
185. Yang B., Gao L., Li L., Lu Z., Fan X., Patel C.A., Pomerantz R.J., DuBois G.C., Zhang H. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 2003, 278:6596-6602.
186. Yang S., Sun Y., Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J. Biol. Chem. 2001, 276:4889-4893.
187. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11:435-442.
188. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
189. Yu Y., Xiao Z., Ehrlich E.S., Yu X., Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004, 18:2867-2872.
190. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990, 61:213-222.
191. Zennou V., Bieniasz P.D. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 2006, 349:31-40.
192. Zennou V., Perez-Caballero D., Gottlinger H., Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 2004, 78:12058-12061.
193. Zhang H., Pomerantz R.J., Dornadula G., Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J. Virol. 2000, 74:8252-8261.
194. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
195. Zhang K.L., Mangeat B., Ortiz M., Zoete V., Trono D., Telenti A., Michielin O. Model structure of human APOBEC3G. PLoS One 2007, 2:e378.
196. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:6073-6076.
197. Zimmerman C., Klein K.C., Kiser P.K., Singh A.R., Firestein B.L., Riba S.C., Lingappa J.R. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 2002, 415:88-92.